LFB
LIVE

Add to watchlist:

No watchlists yet
View on USPTO

LFB Trademark

Serial Number: 79220430 • Registration: 5557831

LFB is a trademark filed by Laboratoire Francais Du Fractionnement et des Biotechnologies, on August 29, 2017. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Laboratoire Francais Du Fractionnement et des Biotechnologies, (38 trademarks)

3, avenue des Tropiques
91958 Courtaboeuf , FR

Entity Type: 99

Trademark Details

Filing Date

August 29, 2017

Registration Date

September 11, 2018

Published for Opposition

June 26, 2018

Goods & Services

[ Editing and publishing of texts other than advertising texts in the field of health; arranging and providing education, training and instruction, namely, providing classes, seminars, symposiums, congresses, conferences, meetings, educational courses, and workshops in the field of health; organization and conducting of seminars, symposiums, congresses, conferences, meetings, educational courses, and workshops, in the field of health ]

[ Medical, veterinary, surgical apparatus and instruments, namely, diagnostic apparatus and instruments in the nature of apparatus for medical diagnostic testing and screening in the field of immunology, haemostasis, intensive care, immune deficiency; apparatus for analysis and diagnosis of disorders or diseases in the field of immunology, haemostasis, intensive care, immune deficiency; medical devices, namely, blood collection kits, disposable cartridge, diagnostic kits consisting primarily of probes, buffers and reagents for use in blood coagulation testing and screening ]

[ Retail store services featuring pharmaceutical preparations and products, and medical devices; wholesale retail store services featuring pharmaceutical preparations and products, and medical devices; import and export agencies in the field of pharmaceutical preparations and products, and medical devices; commercial representation, namely, promoting the goods and services of others; sales promotion ]

[ Scientific and technological services as well as research and design services relating thereto, namely, scientific research, product development, design and testing for new product and engineering in the field of health; industrial analysis and research services in the field of health; scientific research services using protein expression platform technology for research and development of pharmaceuticals; scientific research services using protein expression platform technology for manufacturing protein-based therapeutics; medical and scientific research of recombinant protein platform technologies designed to lead to new human vaccines; conducting scientific studies in the field of immunology, haemostasis, intensive care; research and development of new products for others; scientific research for medical purposes in the field of immunology, haemostasis, intensive care; cellular and molecular biology research; testing of pharmaceutical products; conducting clinical trials for others in the field of immunology, haemostasis, intensive care; engineering; ] advice and assistance in the field of health

[ Medical analysis relating to human blood plasma; ] sampling, collection and preservation of human blood plasma; providing advice and information in the field of health

Pharmaceutical and veterinary products and preparations for the treatment of disorders or diseases in the field of immunology, haemostasis, intensive care; medicines for the treatment of disorders or diseases in the field of immunology, haemostasis, intensive care [ ; diagnostic products for medical and veterinary use for the treatment of disorders or diseases in the field of immunology, haemostasis, intensive care ]

[ Scientific apparatus and instruments, namely, diagnostic apparatus and instruments for calculating and managing drug penetration parameters, for assessing immune deficiency, for laboratory use; downloadable electronic and digital publications, namely, magazines, newsletters, brochures, articles in the field of health; ] downloadable instructional and teaching material, namely, software in the field of health; [ electronic reports featuring results from clinical trials and studies in the field of health; ] recorded software, namely, software for providing medical information in the field of immunology, haemostasis, intensive care, immune deficiency; computer software for educational and commercial activities, namely, software providing information in the field of health; software applications used with medical diagnostic apparatus to calculate and manage immune deficiency or bleeding; computer software for Websites, Intranet and the Internet, namely, software for training and information of patients and health professionals; downloadable computer software applications in the field of health for calculating and managing drug penetration parameters in the human body

Filing History

PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Oct 19, 2025 INPR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
May 20, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
May 20, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
May 20, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
May 20, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
May 20, 2025 COAR
NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Feb 19, 2025 NA71
REGISTERED - PARTIAL SEC 71 ACCEPTED
Feb 19, 2025 71.P
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Feb 18, 2025 APRE
TEAS SECTION 71 RECEIVED
Sep 3, 2024 ES71
NEW REPRESENTATIVE AT IB RECEIVED
May 4, 2024 NREP
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Sep 11, 2023 REM3
CORRECTION FROM THE IB EXAMINED, NO ACTION IS NEEDED
Apr 15, 2021 CORN
NEW REPRESENTATIVE AT IB RECEIVED
Apr 9, 2021 NREP
CORRECTION TRANSACTION RECEIVED FROM IB
Apr 3, 2021 CRCV
NEW REPRESENTATIVE AT IB RECEIVED
Mar 5, 2021 NREP
FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 15, 2019 FINO
GENERIC MADRID TRANSACTION SENT TO IB
Dec 19, 2018 XXSS
GENERIC MADRID TRANSACTION CREATED
Dec 19, 2018 XXCR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 11, 2018 FICR
REGISTERED-PRINCIPAL REGISTER
Sep 11, 2018 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 26, 2018 NPUB
PUBLISHED FOR OPPOSITION
Jun 26, 2018 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 6, 2018 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 21, 2018 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 19, 2018 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 19, 2018 CRFA
ASSIGNED TO LIE
May 16, 2018 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 9, 2018 TROA
REFUSAL PROCESSED BY IB
Jan 19, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Dec 17, 2017 RFCS
REFUSAL PROCESSED BY MPU
Dec 17, 2017 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Dec 7, 2017 RFCR
NON-FINAL ACTION WRITTEN
Dec 6, 2017 CNRT
ASSIGNED TO EXAMINER
Dec 4, 2017 DOCK
APPLICATION FILING RECEIPT MAILED
Nov 21, 2017 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Nov 15, 2017 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Nov 9, 2017 REPR